Statements in which the resource exists as a subject.
PredicateObject
rdf:type
lifeskim:mentions
pubmed:issue
22
pubmed:dateCreated
2005-10-27
pubmed:abstractText
During our search for therapeutic agents to treat diarrhea-predominant IBS, we found that 2-substituted benzoxazole derivatives have a characteristic 5-HT(3) receptor partial agonist activity with high affinity. Some of these compounds showed high in vitro metabolical stability, and 6g showed marked antidiarrhetic activity with little side effect of constipation in in vivo tests. Our results indicate that 5-HT(3) receptor partial agonists might be superior as therapeutic agents to the drugs currently used for IBS treatment.
pubmed:language
eng
pubmed:journal
pubmed:citationSubset
IM
pubmed:chemical
pubmed:status
MEDLINE
pubmed:month
Nov
pubmed:issn
0022-2623
pubmed:author
pubmed:issnType
Print
pubmed:day
3
pubmed:volume
48
pubmed:owner
NLM
pubmed:authorsComplete
Y
pubmed:pagination
7075-9
pubmed:dateRevised
2010-11-18
pubmed:meshHeading
pubmed-meshheading:16250667-Administration, Oral, pubmed-meshheading:16250667-Animals, pubmed-meshheading:16250667-Benzoxazoles, pubmed-meshheading:16250667-Cerebral Cortex, pubmed-meshheading:16250667-Colon, pubmed-meshheading:16250667-Diarrhea, pubmed-meshheading:16250667-Gastrointestinal Transit, pubmed-meshheading:16250667-Guinea Pigs, pubmed-meshheading:16250667-Ileum, pubmed-meshheading:16250667-Irritable Bowel Syndrome, pubmed-meshheading:16250667-Male, pubmed-meshheading:16250667-Mice, pubmed-meshheading:16250667-Microsomes, Liver, pubmed-meshheading:16250667-Muscle, Smooth, pubmed-meshheading:16250667-Muscle Contraction, pubmed-meshheading:16250667-Piperazines, pubmed-meshheading:16250667-Radioligand Assay, pubmed-meshheading:16250667-Rats, pubmed-meshheading:16250667-Rats, Wistar, pubmed-meshheading:16250667-Serotonin 5-HT3 Receptor Agonists, pubmed-meshheading:16250667-Structure-Activity Relationship
pubmed:year
2005
pubmed:articleTitle
Orally active benzoxazole derivative as 5-HT3 receptor partial agonist for treatment of diarrhea-predominant irritable bowel syndrome.
pubmed:affiliation
Pharmaceutical Research Department, Meiji Seika Kaisha, Ltd., 760 Morooka-Cho, Kohoku-ku, Yokohama 222-8567, Japan. satoshi_yoshida@meiji.co.jp
pubmed:publicationType
Journal Article, In Vitro